Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's disease. [electronic resource]
Producer: 20070822Description: 693-702 p. digitalISSN:- 1078-0998
- Adolescent
- Adult
- Aged
- Anti-Inflammatory Agents -- therapeutic use
- Antibodies, Monoclonal -- therapeutic use
- Biomarkers -- blood
- Crohn Disease -- blood
- Enzyme-Linked Immunosorbent Assay
- Follow-Up Studies
- Gene Expression -- drug effects
- Humans
- Immunohistochemistry
- Infliximab
- Matrix Metalloproteinase 2 -- blood
- Matrix Metalloproteinase 9 -- blood
- Middle Aged
- Neutrophils -- enzymology
- RNA, Messenger -- genetics
- Reverse Transcriptase Polymerase Chain Reaction
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.